What if the next breakthrough in drug delivery wasn’t a new molecule, but a revolutionary way to make medicines work longer and safer?

In this episode of Lightning RX, host Colette Nataf, founder of Lightning GTM, sits down with Jeff Missling, CEO of Frenelle Pharma, to discuss how their innovative Pharos platform is transforming long-acting injectable drugs across human and animal health.

Jeff shares how Frenelle Pharma is tackling unmet medical needs by engineering precision biodegradable microspheres that enable safer, more effective treatments. He walks us through their unique hub-and-spoke business model, deploying their platform technology across multiple therapeutic areas, from low back pain to opioid use disorder, and even companion animal health.

The conversation explores the challenges and opportunities of developing long-acting injectable therapies, strategic partnerships in biotech, and the mission-driven approach to expanding access to addiction treatment.

What You’ll Learn:

• How Frenelle Pharma’s Pharos technology enables precise, long-acting drug delivery
• The advantages of a hub-and-spoke business model in biotech innovation
• The unique regulatory pathway and market opportunity in companion animal health
• Addressing safety and adoption barriers for injectable opioid use disorder treatments
• Building strategic partnerships and investor relations in a competitive landscape
• The importance of leadership, communication, and patience in drug development
• How technology can improve patient compliance, outcomes, and quality of life

“Better is always possible; it’s about finding the opportunities where improved delivery can change the patient experience.”

Connect with Jeff Missling:

• LinkedIn: linkedin.com/in/jeff-missling-a410814

• LinkedIn
• Website
• Spotify
• Amazon Music
• iHeart

If you enjoyed this episode, share it with someone passionate about healthcare marketing, startup growth, or innovative product launches, and don’t forget to leave us a review. New episodes drop weekly!